A new review article in Science Advances 2023 – TCR-engineered T cell therapy in solid tumors: State of the art and perspectiveswebmaster@ervaccinetechnologies.com2023-03-01T21:32:37+00:00
Research article in American Journal of Hematology 2022 – HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapywebmaster@ervaccinetechnologies.com2022-06-28T22:19:48+00:00
Research Article in European Journal of Cancer journal 2022 – Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapywebmaster@ervaccinetechnologies.com2022-06-16T07:59:13+00:00
Research Article in Science Advances 2022- Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapywebmaster@ervaccinetechnologies.com2022-01-27T13:13:09+00:00
SITC 2021 – Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapywebmaster@ervaccinetechnologies.com2021-12-17T10:03:07+00:00
Les rétrovirus endogènes humains (HERVs) caractérisent les différentes sous-populations cellulaires normales et leucémiques et constituent un réservoir d’épitopes pour le développement d’immunothérapies dans la LAMwebmaster@ervaccinetechnologies.com2021-12-20T13:54:40+00:00
CIMT 2021 – Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapywebmaster@ervaccinetechnologies.com2021-12-17T09:59:41+00:00
